Enspryng (satralizumab-mwge) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)

Satralizumab is a recombinant humanised monoclonal antibody that targets IL-6 receptor activity. Credit: Business Wire.



  • Enspryng (satralizumab-mwge)
  • Enspryng (satralizumab-mwge)
  • Enspryng (satralizumab-mwge)